부산대학교 도서관

Background Venous thromboembolic disease (VTE) is characterized by obstruction of venous blood flow by a thrombus. Survival data, frequency of disease recurrence, and bleeding rate in patients on anticoagulant therapy with warfarin compared to rivaroxaban in the Latin American population are limited in VTE. Methods A retrospective cohort study with propensity score matching analysis was conducted in patients with pulmonary embolism and/or deep vein thrombosis anticoagulated with warfarin or rivaroxaban treated. Survival analysis was performed using a Kaplan-Meier curve for each of the intervention groups, and it was compared using a Log Rank test. Results Of 2193 potentially eligible patients with a suspected diagnosis of VTE, 505 patients entered the analysis; of these, 285 subjects were managed with warfarin and 220 anticoagulated with rivaroxaban. Major bleeding at 12 months occurred in 2.7% (6/220) of patients treated with Rivaroxaban, compared to 10.2% (29/285) in the Warfarin group in the unmatched population (p = 0.001). In the matched population, bleeding at 12 months occurred in 2.9% (6/209) of patients on Rivaroxaban and in 11.0% (23/209) of patients on Warfarin (p = 0.001). The survival rates at 6 months were 97.1% for Rivaroxaban and 97.6% for Warfarin (p = 0.76). At 12 months, the survival rates were 94.7% for Rivaroxaban and 95.7% for Warfarin (p = 0.61). Conclusion In the treatment of VTE, there is no differences on 6 and 12-month survival or a reduction in the occurrence of new thromboembolic events when comparing rivaroxaban to warfarin. However, a lower risk of major bleeding is observed at 12 months with Rivaroxaban. Keywords: Rivaroxaban, Warfarin, Survival, Venous thromboembolic disease
Author(s): Estefan Ramos-Isaza[sup.1], Eduardo Tuta-Quintero[sup.1], Alirio Bastidas-Goyes[sup.1], Diana Diaz-Quijano[sup.1], Carolina Aponte-Murcia[sup.2], Julian Espitia-Angel[sup.1], Daniel Pinto-Beltran[sup.1], Johan Rincón-Hernández[sup.1], Juan Sánchez-Cuellar[sup.1], Jesus Pérez-Bueno[sup.1] and Luis F. Giraldo-Cadavid[sup.1,3] Introduction Venous thromboembolism (VTE) is [...]